These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 18343274)

  • 41. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
    Wenisch C; Krause R; Széll M; Laferl H
    Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP; Matchar DB; Harnett J; Wilson J
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
    Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
    McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
    Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
    Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
    J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
    Hess G; Hill JW; Raut MK; Fisher AC; Mody S; Schein JR; Chen CC
    Adv Ther; 2010 Oct; 27(10):743-55. PubMed ID: 20799007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a simple educational intervention on the hospital management of community-acquired pneumonia.
    Serisier DJ; Bowler SD
    Respirology; 2007 May; 12(3):389-93. PubMed ID: 17539843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G
    J Emerg Med; 2006 May; 30(4):377-87. PubMed ID: 16740445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
    Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
    Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Peterson AN; Doyle J; Huse DM
    Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
    Pelletier EM; Shim B; Goodman S; Amonkar MM
    Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.